PharmacoEconomics
Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease.
Matthew Walton, Nyanar J Deng, Mark Corbett, Chinyereugo Umemneku-Chikere, Sarah J Nevitt, Helen Fulbright, Chong Yew Tan, Robin Lachmann, Rachel Churchill, Robert Hodgson
Published: 202510.1007/s40273-025-01559-z
Abstract
National Institute for Health and Care Excellence (NICE) technology appraisal processes assume that the standard of care (SoC) is itself cost effective. However, many treatments in use in the UK National Health Service (NHS), particularly in rare dis…
Preview only. Read the full abstract at the source